Mitarbeiter

Prof. Dr. Björn Wängler

Waengler W3-Professor für Molekulare Bildgebung & Radiochemie

E-Mail

 

 

 

 

Prof. Dr. Wängler studierte Chemie und Mathematik an der Johannes Gutenberg-Universität Mainz. Seine Staatsexamensarbeit befasste sich mit der Synthese und Evaluierung neuer PET-Radiopharmaka zu Bestimmung des MGMT Status in Tumoren in vivo. In der anschließenden Doktorarbeit erforschte er neue Methoden zur Früherkennung von Diabetes Mellitus. Die Promotion (2002-2004) mit dem Titel „Synthese, 11C- und 18F-Markierung und Evaluation von Repaglinid-derivaten zur Quantifikation der pankreatischen ß-Zell-Masse in vivo mittels PET“ wurde mit dem Award of the International Isotope Society – Central European Division ausgezeichnet. Nach einer einjährigen Postdoc-Phase am Deutschen Krebsforschungszentrum in der Abteilung Medizinische Physik in der Radiologie in der Juniorgruppe von Prof. Dr. Fabian Kiessling wechselte er als Gruppenleiter in die Radiopharmazeutische Chemie des DKFZ Heidelberg. 2006-2011 war er Forschungsleiter in der Nuklearmedizinischen Klinik der Ludwig-Maximilians-Universität in München, wo er sich 12/2010 habilitierte und 02/2011 die venia legendi erhielt. 07/2010 erhielt er den Ruf auf die W3-Professur für „Molekulare Bildgebung mit Schwerpunkt Radiochemie“ an die Ruprecht-Karls-Universität Heidelberg, 04/2011 den Ruf auf die W2-Professur für „Experimentelle Nuklearmedizin mit Schwerpunkt Radiopharmazeutische Chemie“ an die Ludwigs-Maximilians-Universität.

Den Ruf an die Medizinische Fakultät Mannheim der Universität Heidelberg nahm er 06/2011 zum Wintersemester 2011/2012 an.

Publikationen:  

  1. Pretze M, Wängler C, Wängler B. 6-[18F]Fluoro-L-DOPA: A Well-Established Neurotracer with Expanding Application Spectrum and Strongly Improved Radiosyntheses. Biomed Res Int. 2014;2014:674063.
  2. 2. Hartenbach M, Delker A, Hartenbach S, Schlichtiger J, Niedermoser S, Wängler C, Wängler B, Böning G, Gildehaus FJ, Neumaier K, Lauber K, Kraft K, Belka C, Hacker M, Meineke V, Bartenstein P. Dose-Dependent Uptake of 3'-deoxy-3'-[18F]Fluorothymidine by the Bowel after Total-Body Irradiation. Mol Imaging Biol. 2014 Jun 11, in print.
  3. 3. Rensch C, Lindner S, Salvamoser R, Leidner S, Böld C, Samper V, Taylor D, Baller M, Riese S, Bartenstein P, Wängler C, Wängler B. A solvent resistant lab-on-chip platform for radiochemistry applications. Lab Chip. 2014 Jun 17;14(14):2556-2564.
  4. 4. Fischer G, Wängler B, Wängler C. Optimized solid phase-assisted synthesis of dendrons applicable as scaffolds for radiolabeled bioactive multivalent compounds intended for molecular imaging. Molecules. 2014 May 27;19(6):6952-6974.
  5. 5. Ronellenfitsch U, Wängler B, Niedermoser S, Dimitrakopoulou-Strauss A, Hohenberger P. Importance of PET for surgery of gastrointestinal stromal tumors. Chirurg. 2014 Jun;85(6):493-499.
  6. 6. Seibold U, Wängler B, Schirrmacher R, Wängler C. Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development. Biomed Res Int. 2014;2014:153741.
  7. 7. Zhu J, Chin J, Wängler C, Wängler B, Lennox RB, Schirrmacher R. Rapid 18F-Labeling and Loading of PEGylated Gold Nanoparticles for in Vivo Applications. Bioconjug Chem. 2014 Jun 18;25(6):1143-1150.
  8. 8. Wängler C, Chowdhury S, Höfner G, Djurova P, Purisima EO, Bartenstein P, Wängler B, Fricker G, Wanner KT, Schirrmacher R. Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding? J Med Chem. 2014;57(10):4368-4381.
  9. 9. Lindner S, Michler C, Leidner S, Rensch C, Wängler C, Schirrmacher R, Bartenstein P, Wängler B. Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography. Bioconjug Chem. 2014 Apr 16;25(4):738-749.
  10. 10. Koudih R, Kostikov A, Kovacevic M, Jolly D, Bernard-Gauthier V, Chin J, Jurkschat K, Wängler C, Wängler B, Schirrmacher R. Automated radiosynthesis of N-succinimidyl 3-(di-tert-butyl[18F]fluorosilyl)benzoate ([18F]SiFB) for peptides and proteins radiolabeling for positron emission tomography. Appl Radiat Isot. 2014 Jul;89:146-150.
  11. 11. Lindner S, Michler C, Wängler B, Bartenstein P, Fischer G, Schirrmacher R, Wängler C. PESIN multimerization improves receptor avidities and in vivo tumor targeting properties to GRPR-overexpressing tumors. Bioconjug Chem. 2014 Mar 19;25(3):489-500.
  12. 12. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P, Hacker M. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2014 Feb;270(2):517-525.
  13. 13. Schirrmacher R, Bernard-Gauthier V, Reader A, Soucy JP, Schirrmacher E, Wängler B, Wängler C. Design of brain imaging agents for positron emission tomography: do large bioconjugates provide an opportunity for in vivo brain imaging? Future Med Chem. 2013 Sep;5(14):1621-1634.
  14. 14. Schönberg SO, Wängler B. From molecular imaging markers to personalized image-guided therapy. Z Med Phys. 2013 Feb;23(1):1-2.
  15. 15. Chin J, Vesnaver M, Bernard-Gauthier V, Saucke-Lacelle E, Wängler B, Wängler C, Schirrmacher R. Direct one-step labeling of cysteine residues on peptides with [11C]methyl triflate for the synthesis of PET radiopharmaceuticals, Amino Acids. 2013 Nov;45(5):1097-1108.
  16. 16. Rensch C, Jackson A, Lindner S, Salvamoser R, Samper V, Riese S, Bartenstein P, Wängler C, Wängler B. Microfluidics: A Groundbreaking Technology for PET Tracer Production? Molecules. 2013 Jul 5;18(7):7930-7956.
  17. 17. Fischer G, Seibold U, Schirrmacher R, Wängler B, Wängler C. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules. 2013 Jun 3;18(6):6469-6490.
  18. 18. Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, Niedermoser S, Wängler B, Cumming P, Steiner H, Herms J, Haass C, Bartenstein P. Longitudinal Assessment of Cerebral β-Amyloid Deposition in Mice Overexpressing Swedish Mutant β-Amyloid Precursor Protein Using 18F-Florbetaben PET. J Nucl Med. 2013 Jul;54(7):1127-1134.
  19. 19. Fischer G, Schirrmacher R, Wängler B, Wängler C. Radiolabeled heterobivalent peptidic ligands: an approach with high future potential for in vivo imaging and therapy of malignant diseases. ChemMedChem. 2013 Jun;8(6):883-890.
  20. 20. B. Wängler, A.P. Kostikov, S. Niedermoser S, J. Chin, K. Orchovski, E. Schirrmacher, L. Iovkova-Berends, K. Jurkschat, C. Wängler, R. Schirrmacher: Protein labeling with the labeling precursor [(18)F]SiFA-SH for positron emission tomography. Nat Protoc. 2012 Oct 4;7(11):1964-1969.
  21. 21. A.P. Kostikov, J. Chin, K. Orchovski, E. Schirrmacher, S. Niedermoser, K. Jurkschat, L. Iovkova-Berends, C. Wängler, B. Wängler, R. Schirrmacher: Synthesis of [(18)F]SiFB: a prosthetic group for direct protein radiolabeling for application in positron emission tomography. Nat Protoc. 2012 Oct 4;7(11):1956-1963.
  22. 22. C. Wängler, S. Niedermoser, J. Chin, K. Orchovski, E. Schirrmacher, K. Jurkschat, L. Iovkova-Berends, A.P. Kostikov, R. Schirrmacher, B. Wängler: One-step (18)F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. Nat Protoc. 2012 Oct 4;7(11):1946-1955.
  23. 23. Wängler C, Kostikov A, Zhu J, Chin J, Wängler B, Schirrmacher R (2012) [18F]Fluorine Radiochemistry: Basics, Applications and Challenges. Applied Sciences 2, 277-302.
  24. 24. A.R. Haug, R. Cindea-Drimus, C.J. Auernhammer, M. Reincke, B. Wängler, C. Uebleis, G.P. Schmidt, B. Göke, P. Bartenstein, M. Hacker: The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M. J Nucl Med. 2012 Nov;53(11):1686-1692.
  25. 25. C. Rensch, B. Waengler, A. Yaroshenko, V. Samper, M. Baller, N. Heumesser, J. Ulin, S. Riese, G. Reischl: Microfluidic reactor geometries for radiolysis reduction in radiopharmaceuticals. Appl Radiat Isot. 2012 Aug;70(8):1691-1697.
  26. 26. E. Mille, P. Cumming, A. Rominger, C. La Fougère, K. Tatsch, B. Wängler, P. Bartenstein, G. Böning: Compensation for cranial spill-in into the cerebellum improves quantitation of striatal dopamine D₂/₃ receptors in rats with prolonged [¹⁸F]-DMFP infusions. Synapse. 2012 Aug;66(8):705-713.
  27. 27. C. Cheng, L. Pan, A. Dimitrakopoulou-Strauss, M. Schäfer, C. Wängler, B. Wängler, U. Haberkorn, L.G. Strauss: Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. EJNMMI Res. 2011 Dec 13;1:34.
  28. 28. S. Niedermoser, M. Pape, F.J. Gildehaus, C. Wängler, M. Hartenbach, R. Schirrmacher, P. Bartenstein, B. Wängler: Evaluation of an automated double-synthesis module: efficiency and reliability of subsequent radiosyntheses of FHBG and FLT. Nucl Med Biol. 2012 May;39(4):586-592.
  29. 29. A.P. Kostikov, J. Chin, K. Orcho wski, S. Niedermoser, M.M. Kovacevic, A. Aliaga, K. Jurkschat, B. Wängler, C. Wängler, H.J. Wester, R. Schirrmacher: Oxalic Acid Supported Si-(18)F-Radiofluorination: One-Step Radiosynthesis of N-Succinimidyl 3-(Di-tert-butyl[(18)F]fluorosilyl)benzoate ([(18)F]SiFB) for Protein Labeling. Bioconjug Chem. 2012 Jan 18;23(1):106-114.
  30. 30. A. Rominger, P. Cumming, G. Xiong, G. Koller, G. Böning, M. Wulff, A. Zwergal, S. Förster, A. Reilhac, O. Munk, M. Soyka, B. Wängler, P. Bartenstein, C. la Fougère, O. Pogarell: [(18) F]fallypride PET measurement of striatal and extrastriatal dopamine D(2/3) receptor availability in recently abstinent alcoholics. Addict Biol. 2011 Mar; 17(2):490-503.
  31. 31. A.R. Haug, A. Rominger, M. Mustafa, C. Auernhammer, B. Göke, G.P. Schmidt, Wängler B, P. Cumming, P. Bartenstein, M. Hacker: Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011 Nov;52(11):1679-1683.
  32. 32. L. Iovkova-Berends, C. Wängler, T. Zöller, G. Höfner, K.T. Wanner, C. Rensch, P. Bartenstein, A. Kostikov, R. Schirrmacher, K. Jurkschat, B. Wängler: t-Bu2SiF-derivatized D2-receptor ligands: the first SiFA-containing small molecule radiotracers for target-specific PET-imaging. Molecules. 2011 Sep 2;16(9):7458-7479.
  33. 33. B. Wängler, R. Schirrmacher, P. Bartenstein, C. Wängler: Chelating Agents and their Use in Radiopharmaceutical Sciences. Mini Rev Med Chem. 2011 Oct 1;11(11):968-983.
  34. 34. C. Wängler, M. Schäfer, R. Schirrmacher, P. Bartenstein, B. Wängler: DOTA derivatives for site-specific biomolecule-modification via click chemistry: synthesis and comparison of reaction characteristics. Bioorg Med Chem. 2011 Jun 15;19(12):3864-3874.
  35. 35. L. Iovkova, D. Könning, B. Wängler, R. Schirrmacher, S. Schoof, H.-D. Arndt, K. Jurkschat: SiFA-modified phenylalanine. A key-compound for the efficient synthesis of [18F]-labelled peptides and proteins. Eur. J. Inorg. Chem. 2011, 2238-2246.
  36. 36. C. Wängler, B. Wängler, S. Lehner, A. Elsner, A. Todica, M. Hacker, P. Bartenstein, R. Schirrmacher: A universal gallium-68 labeling technique for protein based imaging agents for in vivo Positron-Emission-Tomography, J. Nucl. Med., 2011Apr;52(4):586-591.
  37. 37. C. Wängler, B. Waser, A. Alke, L. Iovkova, H.G. Buchholz, S. Niedermoser, K. Jurkschat, C. Fottner, P. Bartenstein, R. Schirrmacher, J.C. Reubi, H.J. Wester, B. Wängler: One-step 18F-labeling of carbohydrate-conjugated octreotate-derivatives containing a Silicon-Fluoride-Acceptor (SiFA): In vitro and in vivo evaluation as tumor imaging agents for Positron Emission Tomography (PET), Bioconjug. Chem., 2010, 21(12):2289-2296.
  38. 38. C. Wängler, S. Maschauer, O. Prante, M. Schäfer, R. Schirrmacher, P. Bartenstein, M. Eisenhut, B. Wängler: Multimerization of cRGD peptides via click chemistry: Synthetic strategies, chemical limitations and influence on biological properties, ChemBioChem, 2010, 11(15), 2168-2181.
  39. 39. J. Schmaljohann, E. Schirrmacher, B. Wängler, C. Wängler, R. Schirrmacher, S. Guhlke: Fully automated SPE-based synthesis and purification of 2-[18F]fluoroethyl-choline for human use. Nucl Med Biol, 2011 Feb;38(2):165-170.
  40. 40. A. Rominger, E. Mille, S. Zhang, G. Böning, S. Förster, S. Nowak, F.J. Gildehaus, B. Wängler, P. Bartenstein, P. Cumming: Validation of the „Octamouse“ Holder for Simultaneous microPET [18F]fallypride Recordings from Eight Mice. J Nucl Med, 2010, J. Nucl. Med. 2010, 51(10), 1576-1583.
  41. 41. A.R. Haug, C.J. Auernhammer, B. Wängler, G.P. Schmidt, C. Uebleis, B. Göke, P. Cumming, P. Bartenstein, R. Tiling, M. Hacker: 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors. J. Nucl. Med. 2010, 51(9), 1349-1356.
  42. 42. H. Bartmann, C. Fuest, C. la Fougere, G. Xiong, T. Just, J. Schlichtiger, P. Winter, G. Böning, B. Wängler, A. Pekcec, J. Soerensen, P. Bartenstein, P. Cumming, H. Potschka: Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: Proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia, 2010, 51(9), 1780-1790.
  43. 43. C. Wängler, D. Nada, G. Höfner, S. Maschauer, B. Wängler, S. Schneider, E. Schirrmacher, K.T. Wanner, R. Schirrmacher, O. Prante: In Vitro and Initial In Vivo Evaluation of (68)Ga-Labeled Transferrin Receptor (TfR) Binding Peptides as Potential Carriers for Enhanced Drug Transport into TfR Expressing Cells, Mol Imaging Biol, 2011 Apr;13(2):332-341.
  44. 44. A. Rominger, E. Mille, G. Böning, B. Wängler, C. Arszol, P. Bartenstein, P. Cumming: Alpha(2)-adrenergic drugs modulate the binding of [(18)F]fallypride to dopamine D(2/3) receptors in striatum of living mouse, Synapse, 2010, 64(8), 654-657.
  45. 45. C. la Fougère, G. Pöpperl, J. Levin, B. Wängler, G. Böning, C. Uebleis, P. Cumming, P. Bartenstein, K. Bötzel, K. Tatsch: The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes, J Nucl Med, 2010, 51(4), 581-587.
  46. 46. C. Wängler, R. Schirrmacher, P. Bartenstein, B. Wängler: Click-chemistry reactions in radiopharmaceutical chemistry: fast & easy introduction of radiolabels into biomolecules for in vivo imaging, Curr Med Chem. 2010, 17(11), 1092-1116.
  47. 47. A. Rominger, E. Wagner, E. Mille, G. Böning, M. Esmaeilzadeh, B. Wängler, F.J. Gildehaus, S. Nowak, A. Bruche, K. Tatsch, P. Bartenstein, P. Cumming: Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse, Synapse, 2010, 64(4), 313-322.
  48. 48. C. la Fougère, G. Böning, H. Bartmann, B. Wängler, S. Nowak, T. Just, E. Wagner, P. Winter, A. Rominger, S. Förster, F.J. Gildehaus, P. Rosa-Neto, L. Minuzzi, P. Bartenstein, H. Potschka, P. Cumming: Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar, Neuroimage, 2010, 49(2), 1406-1415.
  49. 49. P. Rosa-Neto, B. Wängler, L. Iovkova, M. Slim, K. Jurkschat, E. Schirrmacher: [(18)F]SiFA-isothiocyanate: A New Highly Effective Radioactive Labeling Agent for Lysine-Containing Proteins, ChemBioChem, 2009, 10(8), 1321-1324.
  50. 50. C. Wängler, R. Schirrmacher, P. Bartenstein, B. Wängler: Simple and convenient radiolabeling of proteins using a prelabeling-approach with thiol-DOTA, Bioorg Med Chem Lett, 2009, 19, 1926-1929.
  51. 51. L. Iovkova, B. Wängler, E. Schirrmacher, R. Schirrmacher, G. Quandt, G. Boening, M. Schürmann, K. Jurkschat: Para-Functionalized Aryl-di-tert-butylfluorosilanes as Potential Labelling Synthons for 18F-Radiopharmaceuticals, Chem-Eur J, 2009, 15(9), 2140–2147.
  52. 52. A. Haug, C. Auernhammer, B. Wängler, R. Tiling, G. Schmidt, B. Göke, P. Bartenstein, G. Pöpperl: Intraindividual comparison of 68Ga-DOTA-TATE- and 18F-DOPA PET in patients with well differentiated metastatic neuroendocrine tumours, Eur J Nucl Med Mol I, 2009, 36(5), 765-70.
  53. 53. B. Wängler, G. Quandt, L. Iovkova, E. Schirrmacher, C. Wängler, G. Boening, M. Hacker, M. Schmoeckel, K. Jurkschat, P. Bartenstein, R. Schirrmacher: Kit like 18F-labeling of proteins: Synthesis of 4-(ditert-butyl[18F]fluoro-silyl)benzenethiol (Si[18F]FA-SH) labeled rat serum albumin for blood pool imaging with PET, Bioconjugate Chem, 2009, 20(2), 317-321.
  54. 54. C. Wängler, G. Moldenhauer, R. Saffrich, E.M. Knapp, B. Beijer, M. Schnölzer, B. Wängler, M. Eisenhut, U. Haberkorn, W. Mier: PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules, Chem-Eur J, 2008, 14(27), 8116-8130.
  55. 55. M. Eder, B. Wängler, S. Knackmuss, F. LeGall, M. Little, U. Haberkorn, W. Mier, M. Eisenhut: Tetrafluorophenolate of HBED-CC; A versatile conjugation agent for 68Ga-labeled antibodies, Eur J Nucl Med Mol I, 2008, 35(10), 1878-86.
  56. 56. C. Wängler, B. Wängler, U. Haberkorn, M. Eisenhut, W. Mier: Applicability of different DOTA building blocks for multiply derivatized scaffolds, Bioorg Med Chem, 2008, 16(5), 2606-2616.
  57. 57. E. Schirrmacher*, B. Wängler*, M. Cypryk, G. Bradtmöller, M. Schäfer, M. Eisenhut, K. Jurkschat, Ralf Schirrmacher: Synthesis of p-(Di-tert-butyl[18F]fluorosilyl)benzaldehyde ([18F]SiFA-A) with High Specific Activity by Isotopic Exchange: A Convenient Labeling Synthon for the 18F-Labeling of N-amino-oxy Derivatized Peptides, Bioconjugate Chem, 2007, 2085-2089.
  58. 58. C. Zhang, B. Wängler, B. Morgenstern, HW. Zentgraf, M. Eisenhut, H. Unterecker, R. Krüger, R. Huss, C. Seliger, W. Semmler, F. Kiessling: Silica- and Alkoxysilane-Coated Ultrasmall Superparamagnetic Iron Oxide Particles: A Promising Tool to Label cells for Magnetic Resonance Imaging, Langmuir, 2007, 23(3), 1427-1434.
  59. 59. B. Wängler, C. Beck, U. Wagner-Utermann, C. Bauer, F. Rösch, R. Schirrmacher, M. Eisenhut: Application of tris-allyl-DOTA in the preparation of DOTA peptide conjugates, Tetrahedron Lett, 2006, 47(33), 5985-5988.
  60. 60. R. Schirrmacher, G. Bradtmöller, E. Schirrmacher, O. Thews, J. Tillmanns, T. Siessmeier, H.G. Buchholz, B. Wängler, C.M. Niemeyer, P. Bartenstein, K. Jurkschat: 18F-Triorganofluorosilanes as tools for the development of silicon based 18F-radiopharmaceuticals: Labelling chemistry for in vivo application, Angew Chem Int Ed, 2006, 45(36), 6047-6050.
  61. 61. O. Calderon Sanchez, A. Mohammed, C. Bauer, M. Wolf, B. Wängler, W. Mier, U. Haberkorn, R. Mocelo, M. Eisenhut: 99mTc Complexes with Activated Ester Functions; Ligands comprising a 3,4-Diamino-benzoate Backbone, Nucl Med Biol, 2006, 33(3), 381-390.
  62. 62. F. Kiessling, M. Heilmann, T. Lammers, K. Ulbrich, V. Subr, P. Peschke, B. Waengler, W. Mier, H.H. Schrenk, M. Bock, L. Schad, W. Semmler: Synthesis and Characterization of HE-24.8: A Polymeric Contrast Agent for Magnetic Resonance Angiography, Bioconjugate Chem, 2006, 17(1), 42-51.
  63. 63. R. Schirrmacher, E. Schirrmacher, B. Kaina, B. Wängler: Synthetic strategies towards O6-substituted guanine derivatives and their application in medicine, Curr Org Synth, 2005, 2, 215-230.
  64. 64. B. Wängler, C.-Y. Shiue, S. Schneider, C. Schwanstecher, M. Schwanstecher, P. Feilen, A. Alavi, F. Rösch, R. Schirrmacher: Synthesis and in vitro evaluation of (S)- 2-([11C]methoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([11C]methyl-Repaglinide): a potential β-cell imaging agent, Bioorg Med Chem Lett, 2004, 14(20), 5205-5209.
  65. 65. B. Wängler, S. Schneider, O. Thews, E. Schirrmacher, S. Comagic, P. Feilen, C. Schwanstecher, M. Schwanstecher, C.-Y. Shiue, S. Höhnemann, M. Piel, F. Rösch, R. Schirrmacher: Synthesis and Evaluation of 2-(2-[18F]Fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): A Novel Radioligand for quantification of pancreatic β-cell mass with Positron Emission Tomography (PET), Nucl Med Biol, 2004, 31, 639-647.
  66. 66. R. Schirrmacher, U. Mühlhausen, B. Wängler, E. Schirrmacher, J. Reinhard, G. Nagel, B. Kaina, M. Piel, M. Wießler, F. Rösch: Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-ß-d-glucosyl)-purine: a novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue, Tetrahedron Lett, 2002, 43(36), 6301-6304.
  67. 67. R. Schirrmacher, B. Wängler, E. Schirrmacher, T. August, F. Rösch: Dimethylpyridin-4-yl-amine-Catalysed Alcoholysis of 2-Amino-N,N,N-trimethyl-9H-purine-6-ylammonium Chloride: An Effective Route to O6-Substituted Guanine Derivatives from Alcohols with Poor Nucleophilicity, Synthesis 2002, 4, 538-542.

 

Patente / Patents:

  1. P. Bartenstein, R. Schirrmacher, B. Wängler, C. Wängler: Kit-Labeling of proteins with Gallium-68 for Positron-Emission-Tomography. Patent application number 61/122,232; date of filing 12.12.2008
  2. M. Jugold, F. Kiessling, R. Pipkorn, W. Semmler, B. Wängler, C. Zhang: uPAR selective contrast agent for magnetic resonance imaging. Patent application number: 06121180.1-2107; date of filing: 25.09.2006
  3. B. Beijer, F. Kiessling, W. Mier, Schulz R, W. Semmler W, B. Wängler: Eine neue Kontrastmittelstrategie für flexible duale PET/SPECT/MRT/NIR Bildgebung. Patent application number: EP06101156.5; date of filing: 01.02.2006

 

zum Seitenanfang/up
Seitenbearbeiter: Carmen Wängler und Björn Wängler
Letzte Änderung: 11.06.2015